Introduction
============

Cortisol, the major human glucocorticoid, is essential for maintenance of normal blood pressure and in excess, either general or local, produces hypertension ([@b28]). Naturally occurring glucocorticoid hypertension in its most florid form, Cushing\'s syndrome, is rare. It is estimated to affect 1 in 300--400 hypertensives in referral centres, and around 5--25 per million of the general population. Iatrogenic Cushing\'s syndrome, on the other hand, is common. Widely used clinically, synthetic glucocorticoids are said to cause hypertension in some 20% of patients, but steroids invariably raise blood pressure in experimental studies ([@b70]). There is considerable interest in the notion that cortisol may play a role in some forms of essential hypertension and it has been suggested that cortisol may contribute to around 30% of all cases of hypertension ([@b64]; [@b50]; [@b34]). There is interest in the role of cortisol in determination of cardiovascular risk ([@b62]; [@b20]; [@b21]).

We have previously examined hemodynamic, volume, metabolic, and hormonal effects of cortisol in a series of studies which have defined the characteristics of cortisol-induced hypertension in normotensive healthy men ([@b73]; [@b13]; [@b40]; [@b82]; [@b78], [@b76], [@b77]; [@b81]; [@b55]; [@b56]; [@b29]; [@b33]). In this review, we discuss changes in cardiovascular risk factors produced by cortisol and factors which might contribute to the blood pressure rise. There is a large range of literature on effects of synthetic glucocorticoids, such as prednisolone and dexamethasone, but this review is confined to consideration of the major naturally occurring adrenocorticosteroid hormone, cortisol. The effect of the synthetic steroid dexamethasone on cardiovascular biomarkers has been delineated recently by [@b6].

Cardiovascular risk factors
===========================

Excess cardiovascular morbidity and mortality is a feature of Cushing\'s syndrome ([@b16]). Untreated Cushing\'s syndrome has a poor prognosis, with only a 50% 5-year survival. Even in treated Cushing\'s syndrome, morbidity remains high, with a very substantial contribution from cardiovascular disease ([@b45]; [@b16]; [@b12]). In subclinical Cushing\'s syndrome, both systolic and diastolic blood pressures were significantly elevated compared with controls due to incidentally discovered adrenal adenoma with mild autonomous cortisol hyperproduction ([@b57]). Patients treated with glucocorticoids also have significantly increased risk of cardiovascular and cerebrovascular disease ([@b52]; [@b68]).

Hypertension
------------

There is good evidence that the elevated blood pressure seen in Cushing\'s syndrome is a consequence of adrenocorticotrophic hormone (ACTH) stimulated increases in cortisol secretion. We have shown that ACTH reproducibly increases blood pressure in both healthy normotensive and hypertensive subjects, but not in patients with Addison\'s disease on steroid replacement. This indicates ACTH hypertension is adrenally dependent ([@b74]). We subsequently showed that the blood pressure raising effects of ACTH were reproduced by cortisol infusion appropriate for conditions of ACTH stimulated cortisol secretion ([@b73]). Although ACTH receptors have been demonstrated in human aortic endothelial cells ([@b23]), it seems unlikely that direct actions of ACTH are involved in ACTH hypertension in humans. Cortisol excess was correlated with the hypertension in Cushing\'s syndrome in a case report ([@b54]), and in 28 patients ([@b51]), but not in all studies ([@b49]). There is no relationship between mineralocorticoid excess and hypertension, and no difference between concentrations of other adrenocortical steroids in Cushing\'s syndrome and essential hypertension ([@b72]). Spironolactone, a mineralocorticoid antagonist, did not significantly lower blood pressure in patients with Cushing\'s syndrome ([@b46]). These observations, together with experimental studies using cortisol, indicate that cortisol is very likely the responsible steroid in the hypertension of Cushing\'s syndrome. Hypertension was a feature of 9/12 of Cushing\'s original cases ([@b15]) and is found in around 80% of cases ([@b41]). We have shown that administration of cortisol to normotensive healthy men reproducibly raises blood pressure ([@b73]; [@b13]; [@b78], [@b76], [@b77]; [@b81]). The increase in plasma cortisol concentration produced by cortisol at 200 mg/day was associated with a highly significant rise in systolic blood pressure ([Table 1](#tbl1){ref-type="table"}).

###### 

Effects on cardiovascular risk factors of cortisol administration (200 mg/day) for 5 days in normotensive healthy men

  Parameter                          n    Control       Cortisol      p
  ---------------------------------- ---- ------------- ------------- ---------
  Plasma cortisol (nmol/L)           33   402 ± 21      1045 ± 73     \<0.001
  Systolic blood pressure (mmHg)     33   117 ± 1       129 ± 1       \<0.001
  Body weight (kg)                   8    70.4 ± 2.8    71.4 ± 2.8    \<0.001
  Fasting plasma glucose (mmol/L)    46   4.1 ± 0.1     5.0 ± 0.2     \<0.001
  Plasma insulin (mU/L               11   16 ± 2.1      22.8 ± 2.1    0.05
  HOMA                               11   1.25 ± 0.18   1.44 ± 0.14   ns
  Plasma cholesterol (mmol/L)        10   4.3 ± 0.3     4.3 ± 0.3     ns
  HDL (mmol/L)                       10   1.1 ± 0.1     1.3 ± 0.1     ns
  LDL (mmol/L)                       10   2.7 ± 0.3     2.6 ± 0.3     ns
  Plasma triglycerides (mmol/L)      10   1.2 ± 0.9     1.1 ± 0.5     ns
  Plasma homocysteine (μmol/L)       6    9.32 ± 0.87   9.72 ± 0.85   ns
  Plasma urate (mmol/L)              6    0.37 ± 0.03   0.28 ± 0.01   0.015
  Plasma vitamin C (μmol/L)          6    29.0 ± 6.7    27.0 ± 4.7    ns
  Plasma vitamin E (μmol/L)          6    24.0 ± 0.7    21.2 ± 2.1    ns
  Plasma t-PA (ng/ml)                6    8.6 ± 0.7     7.4 ± 0.8     0.025
  Plasma PA-1 (ng/ml)                8    6.2 ± 1.3     3.6 ± 1.3     ns
  Corrected serum calcium (mmol/L)   8    2.33 ± 0.02   2.32 ± 0.01   ns

NOTE: Results shown as mean ± s.e.m.

**Abbreviations:** n, number of subjects; HOMA, homeostasis model assessment score; HDL, high density lipoproteins; LDL, low density lipoproteins; ns, nonsignificant; t-PA, tissue plasminogen activator; PA-1, plasminogen activator inhibitor-1

There is some evidence that cortisol excess may be a feature of essential hypertension. [@b32] found higher urinary free cortisol excretion in 153 white patients with essential hypertension than 18 normotensive controls. The authors of the Four Corners Study ([@b67]) observed higher plasma cortisol concentrations in 50 young people with high blood pressure and high parental blood pressure compared with similar numbers of people with lower pressure. Morning plasma cortisol concentrations were elevated in untreated male hypertensives selected from the Paris Prospective Study (total cohort n = 6424) ([@b18]). Systolic blood pressure was related to fasting plasma cortisol concentration in a cohort of 370 English men ([@b37]), but [@b20] found no correlation of cortisol excretion rate with blood pressure in 439 normal Scots. [@b63] examined 226 Swedish subjects in a cross-sectional study and found higher plasma cortisol was independently associated with higher diastolic blood pressure in men, but not women. In another study of 593 English subjects, higher cortisol under the curve during oral glucose tolerance testing was associated with higher systolic blood pressure ([@b43]). In an Indian cohort of 509 subjects, 9 am cortisol was strongly associated with systolic and diastolic blood pressure ([@b66]). Sensitivity to glucocorticoids was also increased in 11 patients with essential hypertension compared with matched normotensive controls ([@b61]).

[@b38] has reviewed evidence for the concept of fetal programming of the neuroendocrine response to stress and the association of increased adrenocortical and sympathoadrenal responses with small size at birth.

The observation that peroxisome proliferator-activated receptor agonists lower blood pressure in humans ([@b25]) is of interest in this regard given their observed effects on downregulation of 11 beta-hydroxysteroid dehydrogenase 1 (11β-HSD1), and hence availability of biologically active glucocorticoids ([@b4]).

Obesity
-------

Truncal obesity is a hallmark of Cushing\'s syndrome. Patients with Cushing\'s disease (n = 25) had higher body mass index and waist to hip ratio than age and sex matched controls ([@b17]). These features persisted in 15 patients who had been cured over 5 years previously ([@b12]). In our studies of short-term cortisol administration (200 mg/day) in normotensive healthy men, weight gain is a feature ([Table 1](#tbl1){ref-type="table"}) and most likely represents salt and water retention over the 5-day period ([@b13]) (see below).

Cortisol excretion rate correlated positively with body mass index and waist and hip measurements in both men and women in a general Scottish population (n = 439), with the relationship persisting in men after multiple regression analysis ([@b20]). A rise of morning salivary cortisol correlated with body mass index, waist-hip ratio, and abdominal sagittal diameter in 28 Swedish men ([@b65]). As discussed by [@b20], the majority of, but not all, studies ([@b53]) found a correlation of urinary cortisol excretion with measures of obesity. Although cortisol excretion was increased, circulating cortisol was not high in most subjects. Indeed, although cortisol secretion is elevated, circulating concentrations may be normal or low ([@b5]). [@b53] speculated that the clear effects of cortisol hypersecretion on body fat as compared with the difficulty in identifying the relationship in normal subjects may reflect differences in potency of cortisol at the target tissue level. In this context, [@b9] suggested central obesity may reflect "Cushing\'s disease of the omentum". They found adipose stromal cells from omental, but not subcutaneous fat, can generate active cortisol from inactive cortisone through expression of 11β-HSDI, and that enzyme expression was increased after exposure to cortisol and insulin. They concluded that in vivo, such a mechanism would ensure constant glucocorticoid exposure specifically to omental fat, leading to central obesity ([@b9]). This group has subsequently shown that in intact undifferentiated omental adipose stromal cells, 11β-HSDI acts primarily as a dehydrogenase, but in mature cells oxoreductase activity dominates. They postulated that as glucocorticoids inhibit cell proliferation, 11β-HSDI activity in uncommitted cells may facilitate proliferation, but once early differentiation is initiated, a switch to oxoreductase activity generates cortisol, promoting adipogenesis ([@b10]). Whorwood and colleagues ([@b80], [@b79]) have speculated that regulation of glucocorticoid receptor isoforms and 11β-HSDI expression in skeletal muscle may play a key role in insulin resistance and that increased receptor expression may contribute to pathogenesis of the metabolic syndrome.

Hyperglycemia
-------------

Glucose intolerance and diabetes mellitus are very common in Cushing\'s syndrome. Fasting glucose was significantly higher in patients with Cushing\'s than those in remission ([@b59]), and in patients (n = 25) than age and sex matched controls ([@b17]). Elevated fasting glucose is also a feature of subclinical Cushing\'s syndrome ([@b57]). Fasting plasma glucose elevation is a common accompaniment of cortisol administration. In our studies, fasting plasma glucose rose consistently in normotensives after 5 days of cortisol administration ([Table 1](#tbl1){ref-type="table"}).

Both fasting and 2-hour stimulated plasma glucose concentrations correlated with 9 am fasting plasma cortisol in the cohort of 370 healthy men born in the UK between 1920 and 1930 studied by [@b37]. [@b62] found increased dermal sensitivity to glucocorticoid correlated with hyperglycemia as well as with hypertension and insulin resistance in 137 men. [@b65] reported a rise in morning salivary cortisol correlated with glucose in 28 Swedish men. In a large study from England (n = 593), [@b43] found plasma cortisol and obesity had independent effects on plasma glucose (although independence should not be interpreted as causality \[[@b7]\]). In a healthy South Asian cohort from Mysore (n = 509), fasting glucose was strongly associated with 9 am plasma cortisol ([@b66]). In patients with glucose intolerance, [@b2] reported that cortisol secretion, although normal, is inappropriately high given enhanced peripheral sensitivity to glucocorticoids.

Insulin resistance
------------------

Insulin resistance is a feature of cortisol excess, both in clinical ([@b57]; [@b17]) and experimental settings ([@b13]). Elevated insulin persists 5 years after cure of Cushing\'s disease ([@b12]). Short-term cortisol administration in our studies of healthy men produced a significant increase in plasma insulin concentration but the homeostasis model assessment score, a measure of insulin resistance, was not significantly increased ([Table 1](#tbl1){ref-type="table"}).

The relationship between glucocorticoids and insulin resistance has been reviewed by [@b3]. [@b37] examined the relationships between size at birth, plasma cortisol concentrations, and components of the insulin resistance syndrome in a cohort of 370 healthy English men born between 1920--1930. Fasting plasma cortisol concentrations were related to systolic blood pressure; plasma glucose: both fasting and 2 hours after an oral glucose tolerance test; plasma triglycerides; and insulin resistance. However, in 151 elderly Finnish women, 24-hour salivary cortisol did not correlate with the metabolic syndrome or birth size ([@b27]).

A positive correlation between morning plasma cortisol concentration and fasting insulin concentration has been reported in healthy elderly Dutch women ([@b53]). In a Finnish study of 71 healthy men, the insulin resistance and hyperinsulinemia of centrally obese subjects was associated with increased urinary cortisol excretion, but circulating cortisol levels were low ([@b24]). [@b65] found a positive association of a rise in morning salivary cortisol with insulin concentration, and [@b66] found a positive association between 9 am cortisol and insulin resistance in a healthy South Asian population (n = 509) born in Mysore between 1934--1954. [@b62] found increased dermal glucocorticoid sensitivity is associated with relative hypertension, insulin resistance, and hyperglycemia in men, including those with a genetic predisposition to hypertension.

[@b42] examined skeletal muscle biopsies from 23 men without fasting hyperglycemia from the Uppsala Longitudinal Study of Adult Men. After adjusting for body mass index, higher levels of skeletal muscle glucocorticoid receptor messenger ribonucleic acid (mRNA) were associated with insulin resistance and with hypertension, but not plasma lipids, glucose, or body mass index alone. They suggested tissue specific variations in glucocorticoid receptor expression and function might provide insights into the pathophysiology of insulin resistance and its association with hypertension ([@b42]). Evidence for the role of neuroendocrine stress in genesis of the metabolic syndrome comes from the work of [@b8] who found 24-hour cortisol metabolite and normetanephrine outputs were higher among cases (n = 30) than controls (n = 153) drawn from the Whitehall II cohort of middle aged working men.

Hyperlipidemia
--------------

Hyperlipidemia is said to be common in Cushing\'s syndrome with hypercholesterolemia and hypertriglyceridemia being prominent ([@b36]). In 25 Italian patients with Cushing\'s, high density lipoprotein (HDL) cholesterol was lower and low density lipoprotein (LDL) cholesterol higher than in matched controls ([@b17]). However, neither total cholesterol nor HDL cholesterol were elevated in Cushing\'s syndrome compared with controls in another study of 41 Italians with active Cushing\'s syndrome ([@b59]). Total cholesterol and triglycerides were elevated in 28 patients in Italy with subclinical Cushing\'s syndrome ([@b57]). In 15 subjects who had had Cushing\'s disease cured over 5 years previously, total and LDL cholesterol and lipoprotein (a) concentrations remained higher than in 30 Italian controls ([@b12]). In 10 normotensive healthy men we found 5 days\' cortisol treatment did not alter plasma cholesterol, triglycerides, HDL, or LDL concentrations ([Table 1](#tbl1){ref-type="table"}). These data suggest that more prolonged periods of cortisol excess are required to produce dyslipidemia.

In a general Scottish population (n = 439), [@b20] found cortisol excretion rate correlated negatively with HDL cholesterol and this correlation remained after multiple regression analysis. In a study of 226 Swedes, [@b63] found higher plasma cortisol associated with higher triglycerides in women, but not in men. In 28 Swedish men, a rise in morning salivary cortisol correlated with triglycerides ([@b65]), and in 509 South Asians, 9 am cortisol was strongly associated with triglyceride concentration ([@b66]).

Other risk factors
------------------

Hyperhomocysteinemia and lower folate concentrations have been reported in 41 Italian patients with Cushing\'s syndrome and homocysteine levels were significantly associated with midnight serum cortisol and serum folate ([@b59]). Folate concentrations were all within the normal range in Cushing\'s syndrome, but homocysteine was elevated. Patients in remission were comparable with controls and the lower folates (4.9 ± 2.8 Cushing\'s, 7.2 ± 2.8 μmol/L control) did not fully account for the increase in homocysteine levels (17.8 ± 4.1 Cushings, 12.3 ± 4.2 μmol/L control) which related to serum cortisol ([@b59]). These same workers reported no differences in fibrinogen concentrations, but prothrombin time was higher and activated partial thromboplastin time lower in Cushing\'s than controls, albeit within the normal range. We found no effect of cortisol on plasma homocysteine concentrations in 6 normotensive healthy men. Plasma urate was decreased, and vitamin C and vitamin E were unchanged. There was a small fall in tissue plasminogen activator, but not in plasminogen activator inhibitor-1 ([Table 1](#tbl1){ref-type="table"}).

[@b17] found higher carotid intimamedia thickness and lower systolic lumen diameter and distensibility coefficient in 25 patients with Cushing\'s disease than controls. Artherosclerotic plaques were found in over 30% of patients. Plaques and carotid intimamedia thickness were also elevated in subclinical Cushing\'s syndrome, as was plasma fibrinogen ([@b57]).

The Norwegian Tromsø study of 460 men and 486 women suggested serum calcium may be a predictor of cardiovascular disease in men ([@b26]). In epidemiologic studies, calcium correlates positively with blood pressure, blood glucose, and serum cholesterol. In our studies of 5 days\' cortisol administration, corrected plasma calcium was unchanged ([Table 1](#tbl1){ref-type="table"}).

Mechanisms of cortisol-induced hypertension
===========================================

Hemodynamics
------------

Both cardiac output and peripheral resistance have been reported to be elevated in Cushing\'s syndrome ([@b1]). Administration of cortisol to normotensive healthy subjects over 5 days leads to elevation of blood pressure, particularly systolic and mean, but also diastolic pressure in some studies, in association with significant increase in cardiac output, but no change in calculated total peripheral resistance ([@b13]; [@b40]). Renal vascular resistance is elevated ([@b13]). The rise in cardiac output may reflect the concomitant rise in plasma volume ([@b13]), but it is not essential for development of hypertension. Pretreatment with the β-blocker atenolol prevented the rise in cardiac output, but did not prevent the rise in blood pressure, which in this case was associated with a rise in peripheral resistance ([@b40]). Conversely, the calcium channel blocker felodipine, which reduces peripheral resistance, had no effect on the rise in blood pressure produced by cortisol, which, in this case, was associated with increased cardiac output ([@b78]). Cortisol-induced hypertension is normally associated with an increase in cardiac output, but the latter is not essential for a blood pressure rise, which can be mediated either by output, or by resistance.

Volume
------

Plasma volume is said to be increased, but total exchangeable sodium was normal in 11 patients with Cushing\'s disease and not correlated with hypertension ([@b44]). Plasma volume, extracellular fluid volume (ECFV), and exchangeable sodium are all increased by cortisol in healthy normotensive subjects ([@b13]). The increase in extracellular fluid volume is unlikely to be essential for the blood pressure rise as sodium restriction completely prevented the rise in ECFV produced by ACTH without abolishing the rise in blood pressure ([@b14]). Adrenocorticotrophic hormone hypertension is explicable solely in terms of increased cortisol secretion ([@b73]). Sodium restriction substantially reduced the rise in exchangeable sodium, but did not modify the rise in plasma volume. However, these factors are unlikely to be critical for cortisol-induced hypertension as the mineralocorticoid antagonist spironolactone, which blocks the sodium retention produced by cortisol, does not prevent the rise in blood pressure ([@b81]). Further, synthetic glucocorticoids, which are natriuretic, produce elevations of blood pressure without any urinary sodium retention or increase in body weight or plasma volume ([@b70]). Cortisol-induced hypertension is not simply explained by mineralocorticoid-induced salt and water retention.

Sympathetic nervous system
--------------------------

Plasma and urine catecholamine concentrations were normal in Cushing\'s disease (n = 11), but cardiac sensitivity to the β-receptor agonist isoprenaline was increased, without increased β-receptor density ([@b44]). In cortisol-treated normotensive healthy subjects measures of sympathetic nervous activity, including plasma catechols ([@b13]), resting noradrenaline spillover rate ([@b39]), reflex sympathetic function, (cold pressor, hand grip, mental arithmetic) ([@b55]), and neuropeptide Y concentrations ([@b76]) were unchanged. Muscle sympathetic vasoconstrictor activity measured directly from peroneal nerve recordings was decreased by cortisol ([@b33]). Hypertension was amplified, not abolished, by autonomic blockade ([@b56]). Cortisol-induced hypertension cannot be ascribed to sympathetic nervous system overactivity. Pressor responsiveness to catechols is increased by cortisol treatment ([@b39]). This may be, at least in part, a consequence of suppression of sympathetic nervous activity.

Vasopressor hormones
--------------------

Cortisol has a range of effects on the renin--angiotensin system. Renin substrate (angiotensinogen) may be increased in Cushing\'s syndrome, but renin and angiotensin are usually normal ([@b58]; [@b44]). Therapy with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists has variable effects ([@b60]; [@b47]). Pressor responsiveness to angiotensin II is increased ([@b47]). In cortisol treated normal subjects, plasma renin and angiotensin II concentrations were decreased ([@b13]). Angiotensin II pressor responsiveness was moderately increased ([@b69]) and this is likely to be explained, at least in part, by decreased plasma concentration of angiotensin II leading to upregulation of angiotensin receptors. The well recognised glucocorticoid stimulated increase in angiotensinogen does not lead to increased plasma angiotensin II concentrations, and it is unlikely to be a key causal mechanism in human glucocorticoid hypertension.

In an Italian study of Cushing\'s disease, vasopressin (AVP) was higher in 13 hypertensives than 11 normotensives and surgical treatment reduced AVP ([@b22]). We did not observe any alteration in plasma AVP concentrations in cortisol-treated normotensive healthy men ([@b13]). Thromboxane has been reported to correlate with cortisol concentrations in both healthy subjects (n = 19) and those at high cardiovascular risk (n = 31) ([@b19]), but information in other conditions is limited. Plasma endothelin concentrations are elevated in Cushing\'s syndrome (n = 13), but did not correlate with blood pressure, plasma cortisol levels, or urinary cortisol excretion ([@b31]). In 9 normotensive healthy men treated with cortisol we observed a nonsignificant rise in urine endothelin excretion after 5 days ([Table 2](#tbl2){ref-type="table"}). The role of insulin as a mediator of hypertension has been the subject of much research. We observed rises in blood pressure and plasma glucose and insulin concentrations in normotensives treated with cortisol, but treatment with the somatostatin analogue octreotide, which reversed the rise in insulin, had no effect on blood pressure, which suggests the two factors are not causally related ([@b77]).

###### 

Effects on vasoactive hormones of cortisol administration (200 mg/day) for 5 days in normotensive healthy men

  Parameter                                    n    Control      Cortisol     p
  -------------------------------------------- ---- ------------ ------------ ---------
  APRC (pmol A1/ml/h)                          16   5.0 ± 0.72   0.7 ± 0.09   \<0.001
  Urine endothelin excretion (ng/day)          9    39 ± 7       52 ± 14      ns
  Urine 6 keto PGF 1α/Cr (ng/mmol)             9    45 ± 7       36 ± 5       ns
  Urine 2, 3 dinor 6 keto PGF1α/Cr (ng/mmol)   9    353 ± 41     462 ± 73     0.039
  Urine cGMP (nmol/day)                        9    522 ± 51     911 ± 961    0.004

NOTE: Results shown as mean ± s.e.m.

**Abbreviations:** APRC, active plasma renin concentration; PG, prostaglandin; Cr, creatinine; cGMP, cyclic guanosine monophosphate; ns, nonsignificant.

Vasodilator hormones
--------------------

Cushing\'s syndrome is reported to be associated with reduced activity of the kallikrein-kinin system and prostaglandins ([@b46]), but in another study kinin system components were higher ([@b48]). Urinary kallikrein activity rose in healthy subjects treated with cortisol ([@b75]). Atrial natriuretic peptide is increased in Cushing\'s syndrome ([@b83]) as it is by cortisol treatment in normal subjects ([@b13]). Accordingly there is no evidence to suggest atrial naturiuretic peptide deficiency is important in the aetiology of the hypertension.

We have measured urinary prostanoids in 9 cortisol-treated normotensive subjects: 6 keto prostaglandin (PG) FIα/creatinine ratio (ng/mmol) was not significantly changed; and 2, 3 dinor 6 keto PG FIα/creatinine (ng/mmol) rose ([Table 2](#tbl2){ref-type="table"}). These studies provide no evidence for vasodilator prostanoid deficiency. Urinary cyclic guanosine monophosphate was also increased ([Table 2](#tbl2){ref-type="table"}). In another study, the cyclooxygenase inhibitor indomethacin did not modify the magnitude of changes in pressor responsiveness to phenylephrine or angiotensin II produced by cortisol ([@b69]).

[@b46] reported low urinary excretion of reactive nitrogen intermediates (a marker of vasodilator nitric oxide activity) in a patient with Cushing\'s syndrome, even after L-arginine administration. In healthy men on a low nitrate diet, we demonstrated that cortisol administration was associated with a fall in plasma reactive nitrogen intermediates, but not in L-arginine or asymmetric dimethyl arginine concentrations ([@b29]). L-arginine did not prevent cortisol-induced rises in blood pressure ([@b30]). Cortisol also inhibits cholinergic dilation in the forearm, similar in magnitude to the inhibition produced by nitric oxide synthase ([@b35]). L-arginine transport is normal in cortisol-treated subjects ([@b11]). Inhibition of vasodilator nitric oxide is a strong candidate for the genesis of glucocorticoid hypertension ([@b29]; [@b71]).

Summary
=======

There is increasing evidence that cortisol contributes to cardiovascular risk, not only in Cushing\'s syndrome, but more generally. Hypertension, truncal obesity, hyperglycemia, insulin resistance, and dyslipidemia are all important in this regard. Glucocorticoid hypertension is not explicable in terms of mineralocorticoid-induced sodium retention and volume expansion. Inhibition of vasodilator nitric oxide is a strong candidate mechanism in the development of hypertension. Therapies should be aimed at lowering cardiovascular risk in patients with Cushing\'s syndrome, which will probably need to target multiple metabolic and hemodynamic abnormalities.
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